EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische Studie

A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia

Jordan Wang, Sabrina Fabi, Deanne Robinson, Shirin Bajaj, Roy Geronemus, Michaela Bell, Alan Widgerow

Journal of Drugs in Dermatology · 2023

DOI: 10.36849/jdd.7340 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Drugs in Dermatology, 2023. Written by Jordan Wang and 6 co-authors. Major MEDLINE topics: Dermatologic Agents, Hyperpigmentation, Melanosis.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Dyschromia can be caused by abnormalities in the increased production and/or reduced clearance of pigmentation in the skin. Causes of hyperpigmentation include excessive sun exposure, medications, hormones, post-inflammatory hyperpigmentation (PIH), and medical disorders, such as melasma. A novel topical product was recently developed, which contains actives that have been validated through in vitro studies to counteract various steps in the pigmentation pathways, including photodamage, PIH, and melasma. This study evaluates the safety and efficacy of this product for facial dyschromia. STUDY DESIGN: Subjects with mild to severe facial dyschromia were enrolled to receive either the novel topical product with PATH-3 Technology (Alastin Skincare, Carlsbad, CA) or hydroquinone 4% topical to apply twice daily. Both cohorts received cleanser, sunscreen, and moisturizer. Follow-up occurred at weeks 4, 8, and 12. Blinded investigators used the modified Melasma Area Severity Index (mMASI) and modified Griffiths scales at baseline and final follow-up. Tolerability assessments and subject questionnaires were completed. RESULTS: Forty-three subjects were enrolled and randomized to either the novel topical product (n=22) or hydroquinone 4% (n=21) cohort. At week 12 follow-up, subjects using the novel topical product had significant improvements in mMASI scores for the right cheek (P=0.0097), left cheek (P=0.0123), combined cheeks (P=0.0019), and total facial area (P=0.0046). In contrast, subjects using hydroquinone 4% had no significant improvements in any of these areas. Although both cohorts demonstrated improvements in dyschromia and skin tone, the novel topical product also offered significant improvements in skin radiance (P=0.0015) and skin texture (P=0.0058), which the hydroquinone 4% cohort did not demonstrate. The hydroquinone 4% cohort experienced 5 adverse events, while there were no adverse events associated with the novel topical product. Subjects in the hydroquinone 4% cohort also more frequently experienced burning/stinging, tingling, itching, erythema, and dryness. CONCLUSION: A novel topical product with PATH-3 Technology, designed to counteract various steps in pigmentation pathways, has been demonstrated to be safe and effective in treating facial dyschromia. CITATION: Wang JV, Fabi SG, Mraz Robinson D, et al. A multi-center, randomized, blinded clinical study evaluating the efficacy and safety of a novel topical product for facial dyschromia. J Drugs Dermatol. 2023;22(4):333-338. doi:10.36849/JDD.7340.

Subjects

MeSH terms (MEDLINE)

Dermatologic AgentsHyperpigmentationMelanosisHumansHydroquinonesTreatment OutcomeAdministration, Cutaneous

Substances

hydroquinoneHydroquinonesDermatologic Agents

Cite

APA

Wang, J., Fabi, S., Robinson, D., Bajaj, S., Geronemus, R., Bell, M., & Widgerow, A. (2023). A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7340

Vancouver

Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, et al. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7340

BibTeX
@article{Wang2023,
  author = {Wang, Jordan and Fabi, Sabrina and Robinson, Deanne and Bajaj, Shirin and Geronemus, Roy and Bell, Michaela and Widgerow, Alan},
  title = {A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  doi = {10.36849/jdd.7340}
}
Start for free →